Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aquestive Therapeutics Inc (AQST)

Aquestive Therapeutics Inc (AQST)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 750,318
  • Shares Outstanding, K 122,003
  • Annual Sales, $ 57,560 K
  • Annual Income, $ -44,140 K
  • EBIT $ -56 M
  • EBITDA $ -44 M
  • 60-Month Beta 1.59
  • Price/Sales 12.57
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 106.04% (-1.60%)
  • Historical Volatility 58.14%
  • IV Percentile 22%
  • IV Rank 5.21%
  • IV High 474.07% on 03/10/25
  • IV Low 85.81% on 11/19/25
  • Expected Move (DTE 14) 0.84 (13.07%)
  • Put/Call Vol Ratio 0.44
  • Today's Volume 3,203
  • Volume Avg (30-Day) 2,316
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 52,575
  • Open Int (30-Day) 65,380
  • Expected Range 5.60 to 7.28

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.14
  • Number of Estimates 6
  • High Estimate -0.11
  • Low Estimate -0.16
  • Prior Year -0.19
  • Growth Rate Est. (year over year) +26.32%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.21 +23.61%
on 11/14/25
6.85 -5.99%
on 11/06/25
+0.36 (+5.92%)
since 11/04/25
3-Month
4.75 +35.58%
on 09/09/25
7.55 -14.70%
on 10/20/25
+1.38 (+27.27%)
since 09/04/25
52-Week
2.12 +203.77%
on 05/13/25
7.55 -14.70%
on 10/20/25
+2.13 (+49.42%)
since 12/04/24

Most Recent Stories

More News
Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

WARREN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 6.44 (+4.72%)
Aquestive Therapeutics: Q3 Earnings Snapshot

Aquestive Therapeutics: Q3 Earnings Snapshot

AQST : 6.44 (+4.72%)
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Planned U.S. launch of Anaphylm™ in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EU Added clinical leadership to drive long-term...

AQST : 6.44 (+4.72%)
Aquestive Therapeutics Announces Leadership Expansion to Support Growth

Changes strategically aligned to support planned launch of Anaphylm™ (dibutepinephrine) Sublingual Film, if approved by the FDA, and to accelerate the Company’s ongoing development initiatives  ...

TLSA : 1.7700 (+4.73%)
AQST : 6.44 (+4.72%)
Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler

WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 6.44 (+4.72%)
Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting

WARREN, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 6.44 (+4.72%)
Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8:00 a.m. ET

WARREN, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement...

AQST : 6.44 (+4.72%)
Aquestive Therapeutics Secures New Patents for Anaphylm

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

AQST : 6.44 (+4.72%)
Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

New patents extend protection for Anaphylm™ into 2037 Anaphylm (dibutepinephrine) Sublingual Film, if approved by the FDA, will be the first and only oral medication for the rescue treatment of severe...

AQST : 6.44 (+4.72%)
Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

NDA remains on track for FDA PDUFA goal date of January 31, 2026 Commercial planning continues enabling rapid launch following approval WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Aquestive...

AQST : 6.44 (+4.72%)

Business Summary

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. It commercializes medicines to solve critical health care problems as well as engages on late-stage proprietary product pipeline which focuses on the treatment of diseases of central nervous system. Aquestive Therapeutics, Inc. is based...

See More

Key Turning Points

3rd Resistance Point 7.04
2nd Resistance Point 6.79
1st Resistance Point 6.62
Last Price 6.44
1st Support Level 6.20
2nd Support Level 5.95
3rd Support Level 5.78

See More

52-Week High 7.55
Last Price 6.44
Fibonacci 61.8% 5.48
Fibonacci 50% 4.84
Fibonacci 38.2% 4.19
52-Week Low 2.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar